TNF as marker of oral candidiasis, HSV infection and mucositis onset during chemotherapy in leukemia patients

Abstract

Objective

To assess changes in the salivary expression of IL-1α,-1β,-2,-6,-10,-17 and TNF in acute leukemia (AL) patients before and during chemotherapy, and its association with HSV infection, oral candidiasis (OC) and oral mucositis (OM) onset.

Methods

Cohort study in AL patients >15 years starting induction chemotherapy at a Mexican oncological center (2013-2014). Oral lesions (OLs) onset was assessed during follow-up, and saliva was obtained at baseline, at visit 2 (days 4-12) and at visit 3 (days 13-21) after chemotherapy; treated with a protease inhibitor and stored at -70°C. An Enzyme-Linked Immunosorbent Assay (ELISA) was performed. Cox proportional hazards regression models were constructed to estimate hazard ratios and its 95% CI (HR, 95% CI) for OLs development.

Results

Forty-one patients were followed-up, 17 (41.5%) developed OL. OL-patients had higher baseline salivary IL-1α than those without lesions (p=0.040). During visit 2, OL-patients had higher levels of IL-1α (p=0.033), IL-1β (p=0.016), IL-6 (p=0.035) and TNF (p=0.019) than those who did not develop OLs. Patients with HSV infection, OC and OM showed higher salivary TNF levels during follow-up (HR: 3.52, 95% CI: 1.35-9.14, p=0.010).

Conclusion

AL patients undergoing chemotherapy with high salivary TNF levels were more likely to develop HSV infection, OC and OM.

This article is protected by copyright. All rights reserved.

http://ift.tt/2o7cypj